OR WAIT null SECS
Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.
Lonza and Bioqube Ventures, a European venture capital firm, have signed a framework agreement for a strategic collaboration under which Lonza will help develop and manufacture biologics and small molecules for Bioqube Ventures’ portfolio companies.
Under the agreement, Lonza will support Bioqube Ventures during the due diligence of candidate biotechs and provide a tailored offering of advice and services to those portfolio companies, according to a Nov. 30, 2021 press release.
Among what Lonza is offering are its expertise and technology to accelerate timelines while mitigating the risks associated with the development and manufacturing of molecules ranging from monoclonal antibodies, complex proteins, and small molecules to antibody-drug conjugates. The company’s approach to drug substance and drug product development and manufacturing simplifies the supply chain, reduces process complexity, and allows for shortened development timelines.
“Bioqube is dedicated to advancing exciting science in the vibrant European ecosystems with the aim of developing breakthrough therapies for patients. This collaboration offers our portfolio companies the opportunity to leverage Lonza's expertise and its global network, supporting our hands-on approach in building new and successful ventures,” said Debora Dumont, co-founder and managing partner, Bioqube Ventures, in the press release.
“This framework agreement provides Bioqube Ventures and its portfolio companies a range of services for its late discovery and early development needs. The cornerstone of our ability to successfully accelerate development programs and commercialize products is our proven track record, comprehensive resources, and the global network that we bring to our customer's portfolio companies. Our customized and scalable solutions demonstrate our commitment to enabling emerging biotechs to take their drug candidates to the clinic,” said Pnina Weitz, global head of Venture Capital Business Development & Relationship Management, Lonza, in the press release.